TrialClinical and vaccine immunology : CVI2012

Treatment with the interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: results of an open-label, parallel-group, randomized single-center study.

A Chioato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.